Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil, +213

The Lancet

Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer +5

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

François‐Clément Bidard, Dieter Peeters, Tanja Fehm, +40

The Lancet Oncology

Metastatic Breast CancerBreast OncologyClinical ValidityIndividual Patient DataMedicine +6

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

Daniela Cardinale, Alessandro Colombo, Rosalba Torrisi, +10

Journal of Clinical Oncology

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale, +199

The Lancet Oncology

Surgical OncologyBreast OncologyMedicineIbcsg 23-01Breast Cancer +5

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad, +21

The Lancet Oncology

Era 223UrologyMedicineClinical TrialsPharmacotherapy +6

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Karim Fizazi, Josep M. Piulats, M. Neil Reaume, +25

New England Journal of Medicine

Very young women (<35 years) with operable breast cancer: features of disease at presentation

Marco Colleoni, Nicole Rotmensz, Chris Robertson, +12

Annals of Oncology

Surgical OncologyBreast OncologyCancer PathologyMedicinePathology +11

Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors

Marco Colleoni, Giuseppe Viale, David Zahrieh, +13

Clinical Cancer Research

Totally implantable central venous access ports for long-term chemotherapy A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days

Roberto Biffi, Filippo de Braud, Franco Orsi, +5

Annals of Oncology

Implantable DeviceSurgical OncologyOncologyEngineeringVenous Disease +8

Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

Giuseppe Curigliano, Giuseppe Viale, Vincenzo Bagnardi, +10

Journal of Clinical Oncology